AstraZeneca Pharma India Limited on December 20, 2020 intimating the receipt of Import and Market Permission in Form CT-20 (Marketing Authorization- Additional Indication) from the Drugs Controller General of India for Benralizumab 30mg/mL solution for injection (FasenraTM). With regard to the same, further update that the company has launched FasenraTM in India on April 20, 2021. Benralizumab (FasenraTM) is indicated as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in adult patients.